-
Most Recent
Search Results
240 results for COV
Regeneron Stock Is a Solid Long-Term Buy
Investors are excited about Regeneron stock for its Covid-19 treatment. They’re missing the point. Regeneron is a great long-term buy.
Speculative Investors Should Buy Sorrento Stock
Sorrento’s drugs could generate a few billion dollars of revenue by the end of 2021, making SRNE stock attractive for speculative investors.
Novavax Stock Has Probably Topped Out Until Successful Clinical Trials
Investors are eyeing clinical results later this month and later this year before committing to buying more NVAX stock.
The InvestorPlace Q&A: Embrace the Food Revolution With the ANEW ETF
The ANEW ETF is investing in companies pushing the boundaries of technology when it comes to feeding the planet. Here’s what you need to know.
Inovio Stock Shows Plenty of Promise Ahead
The clinical results from Inovo’s INO-4700 validate the upside potential in INO stock.
The Breakthrough for Sorrento Could Be Just Around the Corner
If you’d like to wager on a company with a packed clinical pipeline featuring potential Covid-19 treatments, SRNE stock is a great choice.
11 Health Care Stocks to Sell
The theory goes that people will always get sick, so health care stocks will always have healthy profits. Well unfortunately, that’s not true for some.
7 Stocks Raising Dividends This Week
McDonald’s stole the show this week with its dividend increase, but there are other picks that also boosted their yields.
Despite Huge Run, There’s Still Some Upside for Novavax
Though RNA vaccines may have jumped to the lead, the complexities of the Covid-19 crisis gives NVAX stock some extra room to run even higher.
Merck Could Be the Covid-19 Investment You’re Missing
Some traders consider Merck stock to be a safe Dow Jones type of investment. Yet, the Covid-19 vaccine angle could propel the share price.
Novavax Can Still Make Coronavirus Vaccines Great Again
While Pfizer and Moderna enjoy first-to-market advantage, the reality is that being first in a vaccine race isn’t always the best. Plus, Novavax’s distinct approach…
Mutual Funds Spotlight – T. Rowe Price Health Science Fund
The T. Rowe Price Health Science Fund is a great example of sector mutual funds for investors looking to play one industry and capitalize on…
The Risk-to-Reward Proposition for Sorrento Has Gone Bad
Sorrento Therapeutics shareholders witnessed SRNE stock gain 70% in the past month. The risk-to-reward proposition has gone from good to bad.
A Healthy Portfolio Is Heavy in Health Care
Investors would be foolish to ignore the massive demographic shift and growth potential that is boosting health care stocks right now.
Beware: Ocugen Is a Near $2 Billion Company That Has No Revenue
While the market obviously loves Ocugen’s pivot to addressing the Covid-19 pandemic, the reality is that OCGN stock doesn’t come anywhere close to deserving its…
BioNano Genomics Is in a Perfect Bull-Bear Tug of War
Among all the biotech pivots toward the novel coronavirus, BNGO stock represents one of the most sensible. But does that mean shares are a buy?
A Major Shakeup in the Fintech Space
Today’s Digest, from June 2025, arrived as two big themes were beginning to assert themselves – moves by major retailers into stablecoins, and the early…
Stocks Come Out Swinging: Monday’s IP Market Recap
Positive news in construction and manufacturing combined with a number of analyst upgrades to help push the broader indices ahead Monday.
6 – 10 of 240 results
